托拉塞米与呋塞米对心衰住院患者症状和生活质量的影响:TRANSFORM-HF随机临床试验
TRANSFORM-HF试验在美国60家医院纳入2859例心衰住院患者,随机接受托拉塞米或呋塞米利尿策略。12个月时,两组KCCQ-CSS变化无显著差异(调整均差0.06,95%CI -2.26至2.37,P=0.96),PHQ-2≥3比例也无差异(15.1% vs 13.2%,P=0.34)。
要点
- 托拉塞米与呋塞米在12个月时对心衰患者症状和生活质量的影响无显著差异。
- 不同射血分数表型、既往利尿剂使用和基线健康状况亚组中结果一致。
- 两组PHQ-2≥3(支持抑郁评估)的比例无显著差异。
核心结论
- 心衰住院后出院患者中,托拉塞米相比呋塞米策略未在12个月内改善症状或生活质量。
- 托拉塞米与呋塞米对患者报告结局的影响不受射血分数、既往袢利尿剂使用和基线健康状况影响。
研究设计与样本
- TRANSFORM-HF为开放标签、实用性、随机临床试验,在美国60家医院纳入2859例心衰住院患者(不限射血分数)。
- 患者按1:1随机分配至托拉塞米或呋塞米袢利尿剂策略,剂量由研究者选择。
主要发现
- 12个月时KCCQ-CSS变化两组无显著差异(调整均差0.06,95%CI -2.26至2.37,P=0.96)。
- 12个月时PHQ-2≥3比例托拉塞米组15.1%、呋塞米组13.2%(P=0.34)。
- 1个月KCCQ-CSS调整均差1.36(95%CI -0.64至3.36,P=0.18),6个月调整均差-0.37(95%CI -2.52至1.78,P=0.73)。
- 按射血分数表型、随机时NYHA分级和住院前袢利尿剂药物亚组分析结果相似。
- 无论基线KCCQ-CSS三分位如何,两组KCCQ-CSS变化、全因死亡或全因住院均无显著差异。
关键数值与推荐
- KCCQ-CSS范围0-100,100表示最佳健康状况,临床重要差异≥5分。
- PHQ-2范围0-6,评分≥3支持评估抑郁。
- 基线KCCQ-CSS中位数(四分位距):托拉塞米组42(27-60),呋塞米组40(24-59)。
- 基线数据可用性:KCCQ-CSS 2787例(97.5%),PHQ-2 2624例(91.8%)。
临床怎么用
- 对于心衰住院患者,选择托拉塞米或呋塞米策略时,不应期望两者在症状或生活质量改善上存在差异。
- 射血分数、既往袢利尿剂使用和基线健康状况不影响托拉塞米与呋塞米对患者报告结局的比较效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) compared the effect of torsemide versus furosemide on patient-reported outcomes among patients with HF. METHODS: TRANSFORM-HF was an open-label, pragmatic, randomized trial of 2859 patients hospitalized for HF (regardless of ejection fraction) across 60 hospitals in the United States. Patients were randomly assigned in a 1:1 ratio to a loop diuretic strategy of torsemide or furosemide with investigator-selected dosage. This report examined effects on prespecified secondary end points, which included Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; assessed as adjusted mean difference in change from baseline; range, 0-100 with 100 indicating best health status; clinically important difference, ≥5 points) and Patient Health Questionnaire-2 (range, 0-6; score ≥3 supporting evaluation for depression) over 12 months. RESULTS: Baseline data were available for 2787 (97.5%) patients for KCCQ-CSS and 2624 (91.8%) patients for Patient Health Questionnaire-2. Median (interquartile range) baseline KCCQ-CSS was 42 (27-60) in the torsemide group and 40 (24-59) in the furosemide group. At 12 months, there was no significant difference between torsemide and furosemide in change from baseline in KCCQ-CSS (adjusted mean difference, 0.06 [95% CI, -2.26 to 2.37]; P=0.96) or the proportion of patients with Patient Health Questionnaire-2 score ≥3 (15.1% versus 13.2%: P=0.34). Results for KCCQ-CSS were similar at 1 month (adjusted mean difference, 1.36 [95% CI, -0.64 to 3.36]; P=0.18) and 6-month follow-up (adjusted mean difference, -0.37 [95% CI, -2.52 to 1.78]; P=0.73), and across subgroups by ejection fraction phenotype, New York Heart Association class at randomization, and loop diuretic agent before hospitalization. Irrespective of baseline KCCQ-CSS tertile, there was no significant difference between torsemide and furosemide on change in KCCQ-CSS, all-cause mortality, or all-cause hospitalization. CONCLUSIONS: Among patients discharged after hospitalization for HF, a strategy of torsemide compared with furosemide did not improve symptoms or quality of life over 12 months. The effects of torsemide and furosemide on patient-reported outcomes were similar regardless of ejection fraction, previous loop diuretic use, and baseline health status. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03296813.
引用
- Greene SJ, Velazquez EJ, Anstrom KJ, et al. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation. 2023. PMID: 37212600. doi:10.1161/CIRCULATIONAHA.123.064842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。